OSI Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, OSI Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).

16 total trials none currently recruiting 14 completed early-phase tilt top decile by trial count

OSI Pharmaceuticals: 16 sponsored US clinical trials, none currently recruiting.

OSI Pharmaceuticals sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 3 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pancreatic Cancer, with 2 trials.

Top-decile sponsor footprint

OSI Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 58/100

14 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

16 total, page 1 of 1

TERMINATED Phase 2

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

NCT01247922
TERMINATED Phase 2

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

NCT01032070
COMPLETED Phase 1

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

NCT01010945
COMPLETED Phase 3

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors

NCT00373425
COMPLETED Phase 2

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

NCT00294762
COMPLETED Phase 1

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

NCT00294736
COMPLETED Phase 1

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

NCT00139620
COMPLETED Phase 2

A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

NCT00116909
COMPLETED Phase 2

A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer

NCT00088270
COMPLETED Phase 2

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

NCT00085839
COMPLETED Phase 2

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00072631
COMPLETED Phase 2

Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

NCT00073502
COMPLETED Phase 1

Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

NCT00116896
COMPLETED Phase 3

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

NCT00040183
COMPLETED Phase 3

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00036647
COMPLETED Phase 1

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

NCT00033241

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 8
Phase 3 3

Therapeutic Areas

Pancreatic Cancer 2
Must Have Failed First-Line Therapy 1
Locally Recurrent or Metastatic Cancer of the Head and Neck 1
Failed Prior Chemotherapy 1
Advanced Pancreatic Cancer 1
Unspecified Adult Solid Tumor, Protocol Specific 1
Advanced Non-Small-Cell Lung Cancer 1
Non-Small Cell Lung Cancer 1

How the OSI Pharmaceuticals early-phase archive is shaped

16 indexed studies, none listed as recruiting (0% open); 14 completed (88%).

Phase mix: 3 late (III/IV) vs 13 early (I/II) (early-phase heavy).

Top condition: Pancreatic Cancer (2 trials), 7 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

OSI Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

OSI Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%5%10%15% Total trials Recruiting share OSI PharmaceuticalsAccelerated Community Oncology Research NetworkAltimmuneAmerican UniversityAnthera Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
OSI Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

OSI Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 16 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this OSI Pharmaceuticals page

16 registered trials is a research-attention snapshot, not an endorsement of OSI Pharmaceuticals or any single study.

  • None of OSI Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Pancreatic Cancer is the condition OSI Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreatic Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. OSI Pharmaceuticals pipeline card: 16 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.